Element Biosciences has announced an upsized Series E financing round to support the global expansion of its genomic, multiomic, and clinical research technology portfolio. The San Diego-based life sciences company said the round includes $175 million from longtime investor Samsung Electronics, alongside additional undisclosed investment from other backers. The funding is intended to accelerate commercialization, broaden international reach, and advance new products across research, translational science, and diagnostic applications.
Funding to Support Global Expansion
The new capital will help Element scale adoption of its expanding ecosystem of technologies, including its AVITI sequencing platform and the recently introduced VITARI high-throughput benchtop system. The company also plans to support the upcoming launches of AVITI Dx and tissue profiling capabilities on AVITI24. These developments reflect Element’s broader effort to make advanced biological insights more accessible to scientists, clinical researchers, and industry partners worldwide.
Element said the financing will also strengthen its open and interoperable platform architecture. This approach allows pharmaceutical, scientific, and technology partners to build, adapt, and scale applications using Element’s systems. By emphasizing flexibility, the company aims to position its platforms as enabling infrastructure for a wider range of genomic, transcriptomic, protein, spatial, and cellular research workflows.
Samsung Reinforces Confidence in Element’s Strategy
Samsung Electronics, which previously invested in Element, has renewed its backing through a significant contribution to the Series E round. TM Roh, President and Head of Samsung’s Device eXperience Division, said Element has made strong progress since Samsung’s earlier investment. He highlighted the company’s advances in next-generation sequencing, multiomics, and clinical workflows as important to the future of precision medicine and personalized diagnostics.
Samsung’s continued support underscores growing industry interest in technologies that can expand access to sequencing and deepen biological analysis. Roh said Samsung views sequencing as a foundational pillar for precision medicine and expressed confidence in Element’s team, technology, and long-term vision. The investment also aligns with Samsung’s broader focus on medtech, life sciences, and precision medicine initiatives aimed at improving health outcomes.
Building Beyond Sequencing
Element first launched AVITI in 2022 and has since expanded from sequencing into a broader set of scientific tools. Its platforms now support integrated analyses across genetic, molecular, and cellular dimensions, helping researchers generate more comprehensive biological data. The company says this evolution is designed to support foundational research as well as discoveries that contribute to diagnostic and therapeutic development.
Element has also expanded its customer footprint to more than 40 countries. Its users include academic institutions, pharmaceutical companies, biotechnology firms, and clinical research organizations. This international growth gives the company a larger base from which to commercialize new instruments, workflows, and applications.
Advancing a Broader Product Roadmap
The Series E financing comes at a challenging time for many life sciences companies, making the scale of investor support notable. Molly He, CEO and co-founder of Element Biosciences, described the funding as a strong validation of the company’s vision, technology, and execution. She said the investment will help Element continue delivering technologies intended to empower scientific discovery and improve human health.
The company’s near-term roadmap includes advancing AVITI Dx for diagnostic applications and expanding AVITI24 with tissue profiling capabilities. Together with VITARI and the existing AVITI platform, these products are intended to serve a broad range of research and clinical needs. Element’s strategy suggests a focus not only on sequencing performance, but also on creating an integrated ecosystem for multiomic discovery.
Element’s upsized Series E round follows its $277 million Series D financing announced in July 2024. The latest funding remains subject to regulatory approval and is expected to support commercialization, product development, and global expansion. With Samsung’s continued backing and a growing international customer base, Element Biosciences is positioning itself as a key player in the next phase of genomic, multiomic, and clinical research innovation.